Literature DB >> 34458071

Common Dermatologic Conditions in Returning Travelers.

Zachary Shepard1, Margarita Rios2, Jamie Solis3, Taylor Wand3, Andrés F Henao-Martínez1, Carlos Franco-Paredes1, José Antonio Suarez4.   

Abstract

PURPOSE OF REVIEW: Travel medicine practitioners often are confronted with returning travelers with dermatologic disorders that could be of infectious causes or inflammatory or allergic. Some dermatologic processes are the result of exposure to insects or acquired due to environmental exposures. There is a broad range of dermatosis of infectious and non-infectious etiologies that clinicians need to consider in the differential diagnosis of dermatosis in travelers. RECENT
FINDINGS: With increasing international travel to tropical destinations, many individuals may be exposed to rickettsia (i.e., African tick bite fever, scrub typhus, or Mediterranean spotted fever), parasitic infections (i.e., cutaneous larva migrans, cutaneous leishmaniasis, African trypanosomiasis, or American trypanosomiasis), viral infections (i.e., measles or Zika virus infection), bacterial (i.e., Buruli ulcer) or ectoparasites (scabies or tungiasis), and myiasis. Cutaneous lesions provide clinical clues to the diagnosis of specific exposures during travel among returned travelers.
SUMMARY: Dermatologic disorders represent the third most common health problem in returned travelers, after gastrointestinal and respiratory illness. Many of these conditions may pose a risk of severe complications if there is any delay in diagnosis. Therefore, clinicians caring for travelers need to become familiar with the most frequent infectious and non-infectious skin disorders in travelers.

Entities:  

Keywords:  Cutaneous Larva Migrans; Dermatologic; Leishmaniasis; Myiasis; Phytophotodermatitis; Prurigo Nodularis; Travelers; Tungiasis

Year:  2021        PMID: 34458071      PMCID: PMC8389143          DOI: 10.1007/s40475-021-00231-8

Source DB:  PubMed          Journal:  Curr Trop Med Rep


  21 in total

1.  Dermatologic Infectious Diseases in International Travelers.

Authors:  Mary E. Wilson; Lin H. Chen
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

Review 2.  Cellulitis: A Review.

Authors:  Adam B Raff; Daniela Kroshinsky
Journal:  JAMA       Date:  2016-07-19       Impact factor: 56.272

3.  The growing challenge of leishmaniasis in travelers.

Authors:  Carlos Franco-Paredes
Journal:  Travel Med Infect Dis       Date:  2014-11-04       Impact factor: 6.211

Review 4.  The genus Aeromonas: A general approach.

Authors:  Rafael Bastos Gonçalves Pessoa; Weslley Felix de Oliveira; Diego Santa Clara Marques; Maria Tereza Dos Santos Correia; Elba Verônica Matoso Maciel de Carvalho; Luana Cassandra Breitenbach Barroso Coelho
Journal:  Microb Pathog       Date:  2019-03-05       Impact factor: 3.738

5.  Role of ivermectin in the treatment of severe orbital myiasis due to Cochliomyia hominivorax.

Authors:  Johanna Osorio; Ligia Moncada; Alejandra Molano; Sandra Valderrama; Sandra Gualtero; Carlos Franco-Paredes
Journal:  Clin Infect Dis       Date:  2006-08-08       Impact factor: 9.079

Review 6.  Necrotizing Soft-Tissue Infections.

Authors:  Dennis L Stevens; Amy E Bryant
Journal:  N Engl J Med       Date:  2017-12-07       Impact factor: 91.245

Review 7.  A comprehensive review of Vibrio vulnificus: an important cause of severe sepsis and skin and soft-tissue infection.

Authors:  Michael A Horseman; Salim Surani
Journal:  Int J Infect Dis       Date:  2010-12-21       Impact factor: 3.623

Review 8.  Myiasis.

Authors:  Fabio Francesconi; Omar Lupi
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

Review 9.  Ectoparasites: Pediculosis and tungiasis.

Authors:  Sarah J Coates; Cristina Thomas; Olivier Chosidow; Daniel Engelman; Aileen Y Chang
Journal:  J Am Acad Dermatol       Date:  2019-07-13       Impact factor: 11.527

Review 10.  Rickettsioses and the international traveler.

Authors:  Mogens Jensenius; Pierre-Edouard Fournier; Didier Raoult
Journal:  Clin Infect Dis       Date:  2004-10-22       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.